ArticleExpert opinion on drug discovery2011
Strategies for the discovery of therapeutic aptamers.
Article in Expert opinion on drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- RNA Aptamers and Epitranscriptomics: Charting Unexplored Territories in RNA Biology.Molecular diagnosis & therapy · 2026Review
- New Insights into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers.International journal of molecular sciences · 2024Review
- Preparation, applications, and challenges of functional DNA nanomaterials.Nano research · 2023Review
- Therapeutic Potential of Aptamer-Protein Interactions.ACS pharmacology & translational science · 2022Review
- A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2.Molecular therapy. Nucleic acids · 2022Article
- In vitro selection of DNA aptamers against human osteosarcoma.Investigational new drugs · 2022Article
- Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.Frontiers in cell and developmental biology · 2022Review
- X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.Biochimie · 2021Article
- Internalized Functional DNA Aptamers as Alternative Cancer Therapies.Frontiers in pharmacology · 2020Review
- Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.Nucleic acids research · 2018Article
- Selection of PD1/PD-L1 X-Aptamers.Biochimie · 2018Article
- Solid-Phase Synthesis of RNA Analogs Containing Phosphorodithioate Linkages.Current protocols in nucleic acid chemistry · 2017Article
- Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Evoking picomolar binding in RNA by a single phosphorodithioate linkage.Nucleic acids research · 2016Article
- Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Integrative biology : quantitative biosciences from nano to macro · 2014Article
- Aptamers and the next generation of diagnostic reagents.Proteomics. Clinical applications · 2012Review
- X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding.Biochemistry · 2012Article
- Chimeric aptamers in cancer cell-targeted drug delivery.Critical reviews in biochemistry and molecular biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
importance of the fieldTherapeutic aptamers are synthetic, structured oligonucleotides that bind to a very broad range of targets with high affinity and specificity. They are an emerging class of targeting ligand that show great promise for treating a number of diseases. A series of aptamers currently in various stages of clinical development highlights the potential of aptamers for therapeutic applications. AREAS COVERED IN THIS REVIEW: This review covers in vitro selection of oligonucleotide ligands, called aptamers, from a combinatorial library using the Systematic Evolution of Ligands by Exponential Enrichment process as well as the other known strategies for finding aptamers against various targets. WHAT THE READER WILL GAIN: Readers will gain an understanding of the highly useful strategies for successful aptamer discovery. They may also be able to combine two or more of the presented strategies for their aptamer discovery projects. TAKE HOME MESSAGE: Although many processes are available for discovering aptamers, it is not easy to discover an aptamer candidate that is ready to move toward pharmaceutical drug development. It is also apparent that there have been relatively few therapeutic advances and clinical trials undertaken due to the small number of companies that participate in aptamer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.